Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Genmab
Genmab
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Drug Delivery
Partnership advances antibody therapies in immunology
Genmab and argenx have entered a multiyear collaboration, bringing together capabilities to jointly discover, develop and commercialise antibody therapies
Regulatory
ImaginAb announces supply agreement with Genmab
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development
Genmab and Synaffix enter into ADC license agreement
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Manufacturing
Genmab chooses Ibex to take gene candidates to IND in 12 months
New contract extends the partnership between the Danish biotech company and Lonza
Research & Development
Personalised cancer treatment 2.0: new combination strategy developed
Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Ingredients
Tisotumab Vedotin co-developed by Genmab and Seattle Genetics
Genmab and Seattle Genetics announced Seattle Genetics has exercised its option to co-develop tisotumab vedotin
Research & Development
Genmab appoints new CDO
Genmab appoints Judith Klimovsky as Executive Vice President and Chief Development Officer (CDO).
Subscribe now